HRT FINANCIAL LP purchased $1.0M of BIAF

HRT FINANCIAL LP purchased 138,244 shares of bioAffinity Technologies, Inc. (BIAF) at an average of $7.52 ($6.54–$8.59, $1.04M total) across 11 trades over 2026-09-22 to 2026-10-01.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Nov 19, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 19, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BIAF
Bullish
medium confidence
Mentioned
$BIAF
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BIAFBullishLow
01

Why it matters

This provides a fresh, primary-source datapoint on ownership behavior, but it does not include new company fundamentals such as earnings, guidance, financing, or regulatory outcomes.

02

Market read

Traders may treat the filing as a modest sentiment input, but it is unlikely to drive a major repricing without accompanying fundamental catalysts.

03

What to watch

The trades occurred in late September to early October, so the market may have already partially priced any sentiment; also, no 10b5-1 plan is cited, which can cut both ways for interpretation.

Relevance 7/10Novelty 5/10Timing: SEC Form 4 filed 2026-11-19, covering purchases made 2026-09-22 to 2026-10-01.

Background

The article is an SEC Form 4 insider transaction disclosure: HRT Financial LP (10% owner) reported open-market purchases of bioAffinity Technologies, Inc. (BIAF).

Company-level read

Ticker impact

$BIAFBullishMedium confidence
Context

HRT Financial LP, a 10% owner, bought $1.04M of bioAffinity Technologies shares in open-market trades at $6.54 to $8.59 (avg $7.52).

Expected impact

Likely mild upward bias or support as traders interpret the purchase as confidence, though impact should be limited without guidance, earnings, or deal news.

Evidence & confidence

The filing is a primary SEC Form 4 disclosure and the dollar amount is meaningful, but it is still an open-market purchase without stated strategic transaction terms or company-specific fundamentals.

Market effects

Minimal, as this is company-specific insider accumulation with no sector-wide regulatory or competitive signal.

None.

None.

Counterpoint

A large owner purchase can be driven by liquidity needs, diversification, or pre-existing intent rather than a forward-looking bullish thesis.

Key entities

  • bioAffinity Technologies, Inc.

    Subject of the Form 4 insider purchase disclosure (BIAF).

  • HRT Financial LP

    10% owner that purchased $1.04M of BIAF shares via open-market trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BIAFMed

bioAffinity Technologies Reports Q3 2026 Results and 79% Year-to-Date Testing Revenue Growth

bioAffinity Technologies reported Q3 2026 revenue of $1.1M and a net loss of $5.3M. CyPath Lung test sales doubled year-to-date, with testing revenue up 79%. The company had $2.6M in cash at quarter-end. Operating loss widened to $3.5M from $2.3M a year earlier. Physician orders and test reports increased significantly, and the company expanded its distribution network and research collaborations.

$BIAFMed

bioAffinity Technologies, Inc. (BIAF): CyPath® Lung test unit sales double year to date over 2025, with solid gains in physician utilization and recurring orders; testing revenue increases 79%…

bioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release bioAffinity Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath ® Lung Commercialization CyPath ® Lung test unit sales double year to date over 2025, with solid gains in physician utilization and recurring orders; testing rev

$BIAFMed

bioAffinity Technologies to Present Sputum-Based Biomarker Data at CHEST 2026

bioAffinity Technologies will present data at CHEST 2026 on its investigational sputum test, which can detect lung inflammation protein biomarkers linked to asthma and COPD drug targets. The test, not yet FDA cleared, measures biomarkers like TSLP and IL-5, building on the company's CyPath Lung platform. According to the SEC filing, the test may help identify patients for biologic therapies with further validation.